Research portal
Find the target, design the CAR, build the vector that carries it
The research portal is where a CAR-T programme is designed: choosing an antigen, working out whether a CAR can reach it, assembling the construct and its vector, and reading the single-cell data that says whether any of it worked.
What this portal is for
CAR-T AI Agent is built by Cellogen Therapeutics for the people who design these therapies. The research portal holds the discovery and design half of that work, from the first question about a target to the finished vector map and the sequencing run that tests it.
Each tool answers from real data and says where the number came from. Where something cannot be computed from a source we can point at, the tool says so rather than filling the gap with a plausible figure.
The portal is not open to signup. The tools here touch unpublished constructs and patient derived sequencing, so every account is reviewed before it is opened.
Who it is for
- Translational scientists choosing and validating a target
- Programme teams designing constructs and vectors
- Academic groups analysing their own single-cell and sequencing data
What is in it
Discovery
Target Explorer
Look up a target and see where it is expressed, which binders exist against it, and whether a CAR can reach it at all, with the source behind each answer rather than a confidence tier.
Antigen Discovery
Rank candidate antigens on tumour expression, normal tissue expression and surface accessibility, computed as log2 fold change and adjusted p values over TCGA and GTEx through one pipeline.
Single-Cell Analysis
Upload your own matrix or import a public dataset, then run quality control, clustering, annotation, differential expression, pathways, copy number, hashtag demultiplexing, VDJ and CAR-T specific views. Figures export at publication resolution.
CARMSeD
Predicted synergy class and signal strengths for a CAR, scored from the sequence itself, so an untried hinge or a bispecific still gets an answer instead of a lookup miss.
PromoterForge
T cell specific synthetic promoter design, for driving a CAR from a promoter of your own.
Runs as its own application and opens in a new tab.
Design
HelixForge
Design the CAR and the vector that carries it, in one shell. Eight delivery systems from lentivirus to mRNA, parts traced to NCBI and UniProt, a restriction map read on both strands, and map export at 400 or 600 dpi.
CelAbGen
BetaDe novo antibody and nanobody design against your target. Designs should be confirmed at the bench before they go into a programme.
Runs as its own application and opens in a new tab.
Cimmexa
Immunogenicity prediction and de-immunisation for a sequence you are about to take forward.
Runs as its own application and opens in a new tab.
Atlas and assistant
CAR Atlas
Live intelligence on CAR-T trials and the constructs behind them.
Runs as its own application and opens in a new tab.
Research assistant
Ask a question in plain language and get an answer grounded in the current literature and the live web, with every source listed so you can go and read it.
In development
These have a place in the portal but are not open yet. They are listed so the roadmap is visible, not as something you can use today.
- Spatial DataNot open yet
- Cas AI NovaNot open yet
- CelnfoNot open yet
How access works
The portal is not open to signup, and nothing here is granted automatically. A request is read by a person, and the decision comes back by email.
- 1
You ask
Sign in and send the form at the foot of this page, saying what you would use the portal for.
- 2
We read it
A person reads every request. We may write back with a question before deciding.
- 3
You get an email
If it is approved, the portal opens on your next visit. If it is not, you can ask again.
If you are at Cellogen Therapeutics, your account already has it and there is nothing to ask for.
Request access
Access to CAR-T Research Portal is granted per account. Tell us what you need it for and we will reply by email.
Sign in to ask
A request has to come from an account, so that the reply reaches the person who asked. Signing in takes a minute, and you can create an account on the same page.